Pharmaceutical

What’s next for AAV gene therapies in 2024?

Upcoming regulatory events for pipeline AAV gene therapies, with a focus on neuromuscular and blood disorders, are setting high expectations for the space in 2024.

Mar 11, 2024 - 00:00
What’s next for AAV gene therapies in 2024?
Upcoming regulatory events for pipeline AAV gene therapies, with a focus on neuromuscular and blood disorders, are setting high expectations for the space in 2024.
Read the original article

Tags:

Previous Article

Opinion: STAT readers on new CDC Covid guidelines, weight loss drugs and mental ...

Next Article

Have metalenses expanded their reach into the ultraviolet region?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA denies approval for Theratechnologies’ tesamorelin F8

FDA denies approval for Theratechnologies’ tesamorelin F8

Jan 25, 2024

STAT+: Wall Street embraces health insurers after scoring Medicare Advantage payment win

STAT+: Wall Street embraces health insurers after scori...

Apr 7, 2023

Sanofi signs $1.2bn licensing agreement for Novavax’s Covid-19 vaccine

Sanofi signs $1.2bn licensing agreement for Novavax’s C...

May 11, 2024